Product/Composition:- | Efinaconazole Topical Solution |
---|---|
Strength:- | 10% |
Form:- | Topical Solution |
Reference Brands:- | Jublia(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Efinaconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis and damaging fungal cell membranes. It effectively treats toenail onychomycosis, offering benefits like targeted application, high nail penetration, broad antifungal activity, and minimal side effects. It provides rapid, effective relief for fungal nail infections.
Efinaconazole topical solution is approved in the US as Jublia for the treatment of toenail onychomycosis. In the EU, it is regulated by the EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on extensive clinical data and pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and ongoing safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We facilitate efficient market access for efinaconazole topical solutions, ensuring adherence to European and American standards for safe, effective antifungal therapy.